The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial.
BACKGROUND
Limited data are present that have assessed the effects of coenzyme Q10 (CoQ10) intake on cardiometabolic markers in type 2 diabetic patients with coronary heart disease (CHD). This study was done to determine the effects of CoQ10 administration on cardiometabolic markers in overweight diabetic patients with stable myocardial infarction.


METHODS
This randomized double-blind placebo-controlled clinical trial was done among 60 diabetic patients with CHD aged 45-75 years old. Subjects were randomly allocated into two groups to receive either 100 mg/day CoQ10 supplements (n = 30) or placebo (n = 30) for 8 weeks.


RESULTS
Compared with the placebo, CoQ10 intake led to a significant reduction in serum interleukin 6 (IL-6) (-1.7 ± 1.6 vs. 0.8 ± 1.7 ng/l, P < 0.001) and protein carbonyl (PCO) levels (-0.2 ± 0.3 vs. 0.1 ± 0.2 nmol/mg protein, P < 0.001). Supplementation with CoQ10 did not affect serum lipoprotein(a), advanced glycation end-products and thiol concentrations compared with the placebo.


CONCLUSIONS
Overall, this study indicated that CoQ10 intake after 8 weeks among diabetic patients with the stable CHD had beneficial effects on serum IL-6 and PCO levels, but did not alter other cardiometabolic markers.
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan AND Department of Clinical Biochemistry and Genetics, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.
Seyyed Mehdi
SM
Mirhashemi
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Vajiheh
V
Najafi
Department of Cardiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Fariba
F
Raygan
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.
Zatollah
Z
Asemi
Cardiometabolic Markers; Coenzyme Q10; Coronary Heart Disease; Supplementation; Type 2 Diabetes Mellitus